Bio-Rad - Preparing for a Stress-free QC Audit

PharmaKure and Universiti Teknologi MARA (UiTM) announce partnership to advance research in Alzheimer’s Disease diagnosis

Research partnership aims to build strong pharma and academic collaborations in sharing data and clinical samples to develop biomarker-based diagnostics for Alzheimer’s Disease 

PharmaKure, a clinical stage company developing precision medicine for Alzheimer’s Disease and other neurodegenerative diseases, announces a research collaboration agreement with the Faculty of Pharmacy in Universiti Teknologi MARA (UiTM), one of the largest comprehensive universities in Malaysia. The partnership is focused on advancing research initiatives on the use of machine learning tools to predict Alzheimer’s Disease using blood via academic-industry partnerships.

The new relationship aims to translate clinical research from UiTM using PharmaKure’s novel whole blood testing and machine learning technology for identifying early-stage Alzheimer’s Disease to support the development of much needed diagnostic tests worldwide. Pharmakure recently announced a successful study for its proprietary ALZmetrix™ blood-based biomarker test, which together with its machine learning tools can predict which biomarkers are most useful in detecting people at high risk of developing Alzheimer’s Disease. A simple whole blood test such as ALZmetrix may offer an accurate and simple alternative to expensive and invasive PET brain imaging or cerebrospinal fluid (CSF) collection.

“The UK has an ageing population, where 1 in 14 people over the age of 65 have Alzheimer’s Disease. There is an urgent need to not only identify people who will develop this devasting disease, but also develop treatments. This agreement marks a significant milestone in establishing a research collaboration with UiTM, a leading academic institute, allowing us to partner with key experts and enhance our in-house expertise in the analysis of molecular signatures of disease biomarkers associated with Alzheimer’s,” said Dr. Farid Khan, CEO of PharmaKure.

“Earlier and more accurate diagnostics for Alzheimer’s Disease are desperately needed if we are to prevent this devastating disease before profound memory loss takes hold,” said Professor Andrew Doig, Head of R&D at PharmaKure. “We are excited to be forming this relationship which will help us translate research from UiTM to further advance and commercialise diagnostic tests needed worldwide.”

Professor Dato’ Dr. Abu Bakar Abdul Majeed, Dean of Pharmacy Faculty in UiTM said, “Malaysia is expected to be an ageing nation by 2030, with almost half a million dementia patients predicted in 2050. That’s why this research partnership is important; we want to drive innovation and have societal impact both here and across the rest of the world. Alzheimer’s is a complex disease, by combining UiTM’s and PharmaKure’s biomarker, clinical and imaging data together with machine learning algorithms we will gain better understanding of how this disease develops and ultimately find ways to treat it.”

For more information see Pharmakure’s website


Bio-Rad - Preparing for a Stress-free QC Audit

PharmaKure and Universiti Teknologi MARA (UiTM) announce partnership to advance research in Alzheimer’s Disease diagnosis

The EURORealTime SARS-CoV-2 from EUROIMMUN is now validated for use with saliva as sample material as an alternative to throat swabs. Collection of saliva specimens is easier and less distressing for patients than taking nasal or throat swabs, especially for children.

The CE-marked assay provides fast and simple real-time PCR-based detection of SARS-CoV-2 in RNA isolated from the patient samples. Reverse transcription and real-time PCR are performed in one step, so that only one reaction is required per sample.

The test provides high sensitivity due to simultaneous detection of two defined target sequences in the ORF1ab and N genes of the viral genome. The variants alpha (B.1.1.7 lineage), beta (b.1.351 lineage), gamma (P.1 lineage) and delta (B1.617.2 lineage) can be reliably detected.

The test contains an internal amplification control, which serves as an inhibition and extraction control. A SARS-CoV-2 positive control provided in the test kit is analysed as an external control in every test run ensuring dependable results. The complementary EURORealTime Analysis software provides fully automated and standardised evaluation and documentation of results, including all control results. Comprehensive automation options for sample preparation, PCR setup and PCR performance are available.